Rehabilitation pharmacology: Bridging laboratory work to clinical application

Journal of Head Trauma Rehabilitation

Volumn 18, Issue 4, 2003, Pages 342-356

  Phillips, John P ^a   Devier, Deidre J ^b   Feeney, Dennis M ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Amphetamine; Pharmacology; Rehabilitation; Serotonin; Traumatic brain injury

Indexed keywords

ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; AMPHETAMINE; BENZODIAZEPINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CITICOLINE; DEXAMPHETAMINE; DIAZEPAM; DONEPEZIL; DOPAMINE; FLUOXETINE; FLUVOXAMINE; GABAERGIC RECEPTOR AFFECTING AGENT; LEVODOPA; MAPROTILINE; METHYLPHENIDATE; NEUROTRANSMITTER; NORADRENALIN; OXIDOPAMINE; PHENOBARBITAL; PHYSOSTIGMINE; PIRACETAM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THREO 3,4 DIHYDROXYPHENYLSERINE; UNINDEXED DRUG;

BRAIN BLOOD FLOW; BRAIN INJURY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; NORADRENERGIC SYSTEM; OUTCOMES RESEARCH; REHABILITATION MEDICINE; REHABILITATION PHARMACOLOGY; REVIEW;

EID: 0041807583     PISSN: 08859701     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001199-200307000-00005     Document Type: Review

References (109)

1. Narayan R, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma. 2002;19:503-557.
2. The silent epidemic: rehabilitation of people with traumatic brain injury. Rehab Brief IX, 0732-2623, #4. Washington, DC: National Institute of Handicapped Research; 1988.
3. Faden AI. Neuroprotection and traumatic brain injury: the search continues. Arch Neurol. 2001;58:1553-1555.
4. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in ischemic stroke trials through the 20th Century. Stroke. 2001;32:1349-1359.
5. 1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on locomotor activity of rats. Brain Res. 2000;858:393-401.
6. Mouradian RD, Sessler FM, Waterhouse BD. Noradrenergic potentiation of excitatory transmitter action in cerebrocortical slices: evidence for mediation by an alpha 1 receptor-linked second messenger pathway. Brain Res. 1991;546:83-95.
7. Hasselmo ME, Bower JM. Cholinergic suppression specific to intrinsic not afferent fiber synapses in rat piriform (olfactory) cortex. J Neurophysiol. 1992;67:1222-1229.
8. Hasselmo ME, Linster C, Patil M, Ma D, Cekic M. Noradrenergic suppression of synaptic transmission may influence cortical signal-to-noise ratio. J Neurophysiol. 1997;77:3326-3339.
9. McIntosh TK, Yu T, Gennarelli TA. Alterations in regional brain catecholamine concentrations after experimental brain injury in the rat. J Neurochem. 1994;63:1426-1433.
10. Tower D, McEachern D. Acetylcholine and neuronal activity in craniocerebral trauma, J Clin Invest. 1948;27:558-559.
11. Pohl D, Bittigau P, Ishimaru MJ, Stadthaus D, et al. N-methyl-d-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci. 1999;96:2508-2513.
12. Feeney DM, Baron J. Diaschisis. Stroke. 1986;17:817-830.
13. Takasawa M, Watanabe M, Yamamoto S, Hoshi T, et al. Prognostic value of subacute crossed cerebellar diaschisis: single-photon emission CT study in patients with middle cerebral artery territory infarct. AJNR. 2002;23:189-193.
14. Gold L, Lauritzen M. Neuronal deactivation explains decreased cerebellar blood flow in response to focal cerebral ischemia or suppressed neocortical function. Proc Natl Acad Sci. 2002;99:7699-7704.
15. Small SL, Hlustik P, Noll DC, Genovese C, Solodkin A. Cerebellar hemispheric activation ipsilateral to the paretic hand correlates with functional recovery after stroke. Brain. 2002;125:1544-1557.
16. Seltz RJ, Azari NP, Knorr U, Binkofski F, Herzog H, Freund HJ. The role of diaschisis in stroke recovery. Stroke. 1999;30:1844-1850.
17. Whyte J, Vaccaro M, Grieb-Neff P, Hart T. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. J Head Trauma Rehab. 2002;17:284-299.
18. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982;217:855-857.
19. Feeney DM. Amphetamine restores locomotor function after motor cortex injury in the rat. Proc West Pharmacol Soc. 1981;24:15-17.
20. Hovda DA, Feeney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res. 1984;298:358-361.
21. Feeney DM, Hovda DA. Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation. Brain Res. 1985;342:352-356.
22. Sutton RL, Feeney DM. α-noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. RestorNeurol Neurosci. 1992;4:1-11.
23. Kline AE, Chen MJ, Tso-Olivas DY, Feeney DM. Methylphenidate treatment following ablation-induced hemiplegia in rat: experience during drug action alters effects on recovery of function. Pharmacol Biochem Behav. 1994;48:773-779.
24. Feeney DM. From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. Adv Neurol. 1997;73:383-94.
25. Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci. 2000;27:97-105.
26. Mintz M, Tomer R. Exposure to amphetamine after substantia nigra lesion interferes with the process of behavioral recovery. Pharmacol Biochem Behav. 1986;25:1307-1311.
27. Boyeson MG, Feeney DM. Adverse effects of catecholaminergic agonists and antagonists on recovery of locomotor ability following unilateral cerebellar ablations. Restor Neurol Neurosci. 1991;3:227-233.
28. Mattay VS, Berman KF, Ostrem JL, Esposito G, et al. Dextroamphetamine enhances "neural network-specific" physiological signals: a positronemission tomography rCBF study. J Neurosci. 1996;16:4816-4822.
29. Ziemann U, Tam A, Butefisch C, Cohen LG. Dual modulating effects of amphetamine on neuronal excitability and stimulation-induced plasticity in human motor cortex. Clin Neurophysiol. 2002;113:1308-1315.
30. Butefisch CM, Davis BC, Sawaki L, Waldvogel D, et al. Modulation of use-dependent plasticity by damphetamine. Ann Neurol. 2002;51:59-68.
31. Plewnia C, Bartels M, Cohen L, Gerloff C. Noradrenergic modulation of human cortex excitability by the presynaptic alpha(2)-antagonist yohimbine. Neurosci Lett. 2001;307:41-44.
32. Forsyth R, Baxter P, Elliott T. Routine intracranial pressure monitoring in acute coma. Cochrane Database Syst Rev. 2001(3):CD002043.
33. Crisostomo EA, Duncan PW, Propst M, et al. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol. 1988;23:94-97.
34. Redding MH, Solomon B, Borucki S. Effect of dextroamphetamine on motor recovery after stroke. Neurology. 1995;45(Suppl 4):A222.
35. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabi. 1998;79:1047-1050.
36. Walker-Batson D, Smith P, Curtis S, et al. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Stroke. 1995;26:2254-2259.
37. Walker-Batson D, Curtis S, Natarajan RF, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001;32:2093-2098.
38. Sonde L, Nordstrom M, Nilsson CG, et al. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis. 2001;12:253-257.
39. Zabik JE, Levine RM, Maickel RP. Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. Pharmacol Biochem Behavior. 1978;8:429-435.
40. Riffe WH, Ludden TM, Wilcox, et al. Brain and plasma concentrations of amphetamine isomers in mice. J Pharmacol Exp Therapeutics. 1978;206:586-594.
41. Nishino K, Sasaki T, Takahashi K, et al. The norepinepherine precursor L-threo-3,4-dihydroxyphenylserine facilitates motor recovery in chronic stroke patients. J Clin Neurosci. 2001;8:547-550.
42. Boyeson MG, Feeney DM. Striatal dopamine after cortical injury Exp Neurol. 1985;89:479-483.
43. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: part 1. J Head Trauma Rehab. 2000;15:1179-1182.
44. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7:35-49.
45. Scheidtmann K, Fries W, Müller F, Koenig E. L-dopa combined with physiotherapy improves functional motor recovery after stroke. Lancet. 2001;358: 787-790.
46. Mukand JA, Guilmette TJ, Allen DG, et al. Dopaminergic therapy with carbidopa L-dopa for left neglect after stroke: a case series. Arch Phys Med Rehabil. 2001;82:1279-1282.
47. Dobkin BH, Hanlon R. Dopamine agonist treatment of antegrade amnesia from a mediobasal forebrain injury. Ann Neurol. 1993;33:313-316.
48. McDowell S, Whyte J, D'Esposito. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain. 1998;121:1155-1164.
49. Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioral efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999;13:863-872.
50. Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Archives of Physical Medicine & Rehabilitation. 2001;82(3):311-5.
51. Karli DC, Burke DT, Kim HJ, et al. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj. 1999;13:63-68.
52. Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neurosci. 1993;16:346-352.
53. Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neurolmage. 2002;15:26-36.
54. Hindmarch I. The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1995;9:13-17.
55. Hasbroucq T, Rihet P, Blin O, Possamai C-A. Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett. 1997;229:204-208.
56. Blandina P, Goldfarb J, Walcott J, Green JP. Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Therapeutics., 1991;256:341-347.
57. Kanthan R, Shuaib A, Griebel R, et al. Evaluation of monoaminergic neurotransmitters in the acute focal ischemic human brain model by intracerebral in vivo microdialysis. Neurochem Res. 1996;21:563-566.
58. 1A receptor agonist repinotan HCL attenuated histopathology and spatial learning deficits following TBI in rats. Neuroscience. 2001;106:547-555.
59. 1A receptor and recovery of cognitive function after TBI in rats. Am J Phys Med Rehabil. 2002;81:364-372.
60. Boyeson MG, Harmon RL, Jones JL. Comparative effects of fluoxetine, amitriptyline and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil. 1994;73:76-83.
61. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211-1214.
62. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351-359.
63. Öhman J, Braakman R, Legout V. Repinotan (BAY x 3702): a 5HT1a agonist in traumatically brain injured patients. J Neurotrauma. 2001;18:1313-1321.
64. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2002;50:718-729.
65. Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002;17:314-321.
66. Feeney DM, Sutton RL. Pharmacotherapy for recovery of function after brain injury. Crit Rev Neurobiol. 1987;3:135-197.
67. Kojic L, Gu Q, Douglas RM, Cynader MS. Laminar distribution of cholinergic- and serotonergic-dependent plasticity within kitten visual cortex. Dev Brain Res. 2001;126:157-162.
68. Ji W, Gao E, Suga N. Effects of acetylcholine and atropine on plasticity of central auditory neurons caused by conditioning in bats. J Neurophysiol. 2001;86:211-225.
69. Thiel CM, Friston KJ, Dolan RJ. Cholinergic modulation of experience-dependent plasticity in human auditory cortex. Neuron. 2002;35:567-574.
70. Sawaki L, Boroojerdi B, Kaelin-Lang A, et al. Cholinergic influences on use-dependent plasticity. J Neurophysiol. 2002;87:166-171.
71. McIntosh TK, Juhler M, Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury. J Neurotrauma. 1998; 15:731-769.
72. Schmidt RH, Grady MS. Loss of forebrain cholinergic neurons following fluid-percussion injury: implications for cognitive impairment in closed head injury. J Neurosurg. 1995;83:496-502.
73. Groman LK, Fu K, Hovda DA, et al. Effects of traumatic brain injury on the cholinergic system in the rat. J Neurotrauma. 1996;13:457-463.
74. Leonard JR, Grady MS, Lee ME, et al. Fluid percussion injury causes disruption of the septohippocampal pathway in the rat. Exp Neurol. 1997;143:177-187.
75. Hepler DJ, Olton DS, Wenk GL, et al. Lesions in nucleus basilis magnocellularis and medial septal area of rats produce qualitatively similar memory impairments. J Neurosci. 1985;5:866-873.
76. Miyamoto M, Kato J, Narumi S, et al. Characteristics of memory impairment following lesioning of the basal forebrain and medial septal nucleus in rats. Brain Res. 1987;419:19-30.
77. Lyeth BG, Ray M, Mann RJ, Schnabel J, et al. Postinjury scopolamine administration in experimental traumatic brain injury. Brain Res. 1992;569:281-286.
78. Dixon CE, Ma X, Marion DW. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma. 1997;14:161-169.
79. Levin HS. Treatment of postconcussional symptoms with CDP-choline. J Neurol Sci. 1991; 103(Suppl):S39-S42.
80. Lozano R. CDP-choline in the treatment of cranio-encephalic traumata. J Neurol Sci. 1991; 103(Suppl):S43-S47.
81. Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent Nerv Syst Trauma. 1986;3:333-342.
82. Cardenas DD, McLean A Jr, Farrell-Roberts L, Baker L, Brooke M, Haselkorn J. Oral physostigmine and impaired memory in adults with brain injury. Brain Inj. 1994;8:579-587.
83. Goldberg E, Gerstman LJ, Mattis S, et al. Selective effects of cholinergic treatment on verbal memory in posttraumatic amnesia. J Clin Neuropsychol. 1982;4:219-234.
84. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 1998;12:77-80.
85. Masanic CA, Bayley MT, VanReekum R, Simard M. Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil. 2001;82:896-901.
86. Stancheva S, Papazova M, Alova L, Lazarova-Bakarova M. Impairment of learning and memory in shuttle box-trained rats neonatally injected with 6-hydroxydopamine. Effects of nosotropic drugs. Acta Physiol Pharmacol Bulg. 1993;19:77-82.
87. Genkova-Papasova M, Lazarova-Bakarova M. Learning and memory impairment in albino rats after potassium ethylxanthogenate. Effects of nootropic agents. Acta Physiol Pharmacol Bulg. 1991;17:75-83.
88. Stancheva SL, Alova LG. Biogenic monoamine uptake by rat brain synaptosomes during aging. Effects of nootropic drugs. Gen Pharmacol. 1994;25:981-987.
89. Nalini K, Karanth KS, Rao A, Aroor AR. Effects of piracetam on retention and biogenic amine turnover in albino rats. Pharmacol Biochem Bebav. 1992;42:859-864.
90. Bhattacharya SK, Upadhyay SN, Jaiswal AK, Bhattacharya S. Effect of piracetam, a nootropic agent, on rat brain monoamines and prostaglandins. Indian J Exp Biol. 1989;27:261-264.
91. Ricci S, Celani MG, Cantisani AT, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2002; vol 1.
92. De Deyn PP, Reuck JD, Deberdt W, et al. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke. 1997;28:2347-2352.
93. Murphy N, Kazek MP, Van Vleymen B, et al. Economic evaluation of Nootropil in the treatment of acute stroke in France. Pharmacol Res. 1997;36:373-380.
94. Platt D, Horn J, Summa J, et al. On the efficacy of piracetam in geriatric patients with acute cerebral ischemia: a clinical controlled double-blind study. Arch Gerontol Geriatr. 1993;16:149-164.
95. Enderby P, Broeckx J, Hospers W, et al. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin Neuropharmacol. 1994;17:320-331.
96. Kessler J, Thiel A, Karbe H, Heiss WD. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients, Stroke. 2000;31:2112-2116.
97. Boyeson MG. Harmon RL. Effects of trazodone and desipramine on motor recovery in brain-injured rats. Am J Phys Med Rehabil. 1993;72:286-293.
98. Reinhard DL, Whyte J, Sandel ME. Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Arch Phys Med Rehabil. 1996;77:80-83.
99. Mysiw WJ, Jackson RD, Corrigan JD. Amitriptyline for post-traumatic agitation. Am J Phys Med Rehabil. 1988;67:29-33.
100. Fugate LP, Spacek LA, Kresty LA, et al. Measurement and treatment of agitation following traumatic brain injury: II. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabi. 1997;78:924-928.
101. Feeney DM, Westerberg VS. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol. 1990;44:233-252.
102. Stibick DL, Feeney DM. Enduring vulnerability to transient reinstatement of hemiplegia by prazosin after traumatic brain injury. J Neurotrauma. 2001;18:303-312.
103. Goldstein LB, Bullman S. Differential effects of haloperidol and clozapine on motor recovery after sensorimotor cortex injury in rats. Neurorehabil Neural Repair. 2002;16:321-325.
104. Brailowsky S, Knight RT, Blood K. Gamma-aminobutyric acid-induced potentiation of cortical hemiplegia. Brain Res. 1986;362:322-330.
105. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Res. 1986;379:104-111.
106. Hernandez TD, Holling LC. Disruption of behavioral recovery by the anti-convulsant phenobarbital. Brain Res. 1994;635:300-306.
107. Brailowsky S, Knight RT, Efron R. Phenytoin increases the severity of cortical hemiplegia in rats. Brain Res. 1986;376:71-77.
108. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rebabil. 2001;82:1155-1163.
109. Goldstein LB. Common drugs may influence motor recovery after stroke. Neurology. 1985;45:865-871.